| Date Filed | Type | Description |
| 08/14/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 05/15/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/14/2023 |
SC 13G/A
| Rock Springs Capital Management LP reports a 0% stake in Sierra Oncology, Inc. |
| 02/14/2023 |
SC 13G/A
| Rock Springs Capital Management LP reports a 0% stake in PhaseBio Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| Rock Springs Capital Management LP reports a 4.9% stake in Mirum Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| Rock Springs Capital Management LP reports a 4.2% stake in Compass Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Rock Springs Capital Management LP reports a 7.8% stake in Tempest Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Rock Springs Capital Management LP reports a 6.9% stake in Spruce Biosciences, Inc. |
| 02/14/2023 |
SC 13G/A
| Rock Springs Capital Management LP reports a 5.3% stake in MEREO BIOPHARMA GROUP PLC |
| 02/14/2023 |
SC 13G/A
| Rock Springs Capital Management LP reports a 7.6% stake in Inozyme Pharma, Inc. |
| 02/14/2023 |
SC 13G/A
| Rock Springs Capital Management LP reports a 7.3% stake in Immunocore Holdings plc |
| 02/14/2023 |
SC 13G
| Rock Springs Capital Management LP reports a 5.6% stake in AEGLEA BIOTHERAPEUTICS, INC. |
| 02/14/2023 |
SC 13G
| Rock Springs Capital Management LP reports a 5.4% stake in AGIOS PHARMACEUTICALS, INC. |
| 02/14/2023 |
SC 13G/A
| Rock Springs Capital Management LP reports a 5.9% stake in Aclaris Therapeutics, Inc. |
| 02/14/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 11/14/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 08/15/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 05/16/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 04/25/2022 |
SC 13G
| Rock Springs Capital Management LP reports a 6.1% stake in Inozyme Pharma, Inc. |
| 02/15/2022 |
SC 13G
| Rock Springs Capital Management LP reports a 5.1% stake in MEREO BIOPHARMA GROUP PLC |
| 02/14/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2022 |
SC 13G/A
| Rock Springs Capital Management LP reports a 6.9% stake in Spruce Biosciences, Inc. |
| 02/14/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2022 |
SC 13G/A
| Rock Springs Capital Management LP reports a 5% stake in Mirum Pharmaceuticals, Inc. |
| 02/14/2022 |
SC 13G/A
| Rock Springs Capital Management LP reports a 5.6% stake in Immunocore Holdings plc |
| 02/14/2022 |
SC 13G/A
| Rock Springs Capital Management LP reports a 5.4% stake in Compass Therapeutics, Inc. |
| 02/14/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 01/10/2022 |
3
| Rock Springs Capital Management LP (10% Owner) has filed a Form 3 on Tempest Therapeutics, Inc. |
|